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Global evaluations of Parkinson’s disease (PD) severity are available, but their concordance and accuracy have not been previously
tested. The present international, cross-sectional study was aimed at determining the agreement level among four global scales for
PD (Hoehn and Yahr, HY; Clinical Global Impression of Severity, CGIS; Clinical Impression of Severity Index, CISI-PD; and Patient
Global Impression of Severity, PGIS) and identifying which of them better correlates with itemized PD assessments. Assessments
included additional scales for evaluation of the movement impairment, disability, affective disorders, and quality of life. Spearman
correlation coefficients, weighted and generalized kappa, and Kendall’s concordance coefficient were used. Four hundred thirty
three PD patients, 66% in HY stages 2 or 3, mean disease duration 8.8 years, were analyzed. Correlation between the global scales
ranged from 0.60 (HY with PGIS) to 0.91 (CGIS with CISI-PD). Kendall’s coefficient of concordance resulted 0.76 (Po0.0001). HY and
CISI-PD showed the highest association with age, disease duration, and levodopa-equivalent daily dose, and CISI-PD with measures
of PD manifestations, disability, and quality of life. PGIS and CISI-PD correlated similarly with anxiety and depression scores. The
lowest agreement in classifying patients as mild, moderate, or severe was observed between PGIS and HY or CISI-PD (58%) and the
highest between CGIS and CISI-PD (84.3%). The four PD global severity scales agree moderately to strongly among them; clinician-
based ratings estimate PD severity, as established by other measures, better than PGIS; and the CISI-PD showed the highest
association with measures of impairment, disability, and quality of life.
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INTRODUCTION
Patient assessment integrates the data coming from health
professional interview and examination, ancillary proofs (biologi-
cal assays, performance measures, and imaging), self-assessment
by patients and, eventually, by proxy evaluations. The combina-
tion of findings from these sources supports the diagnosis and
allows determining the severity of the disorder with therapeutic
and prognostic purposes. Although standardized thresholds for
allocation of the severity degree can be available for some results,
the assignment of a global severity level is frequently carried out
in an intuitive manner based on previous experience and the
observed data. To help in this purpose, some ‘global impression’
instruments have been developed and are widely applied.1–3
Global evaluations of severity intend providing holistic informa-
tion on the severity of the disorder which is convenient, for
example, for recording and sharing information, classification of
patients for resources assignment, and other purposes. The main
advantage of this kind of assessment is the approach to an
immediate overall appraisal of the health state, whereas their
main disadvantage is the lack of detailed information on the
health state components.
Parkinson’s disease (PD) is a complex neurodegenerative
disorder manifested through typical motor impairment and
complications, a diversity of non-motor symptoms, and progres-
sive disability. Observable signs (e.g., tremor or freezing)
and performance measures are assessed by a professional rater,
but the evaluation of symptoms (e.g., pain, anxiety) and other
subjective aspects (e.g., quality of life, satisfaction with care) needs
the input of patients. However, it is recognized that perceptions
on the patients’ condition frequently differ between patients
themselves and their doctors,4,5 making difficult sometimes to
decide which of these evaluations is more reliable. Determining
the severity level of PD is a challenge not only by these
discrepancies, but also because the expression of the disorder
greatly varies from case to case in components and their relative
importance.
In a previous study,6 we collected information from four global
scales to determine cutoff points for assignment of primary
severity levels to the scores of the Movement Disorder Society
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sponsored version of the Unified Parkinson’s Disease Rating Scale
(MDS-UPDRS). These four scales were the Hoehn and Yahr staging
(HY),7 the Clinical Global Impression-Severity (CGIS),1 the Patient
Global Impression-Severity (PGIS),2,8 and the Clinical Impression of
Severity Index for Parkinson’s disease (CISI-PD).9,10 Two of these
instruments are generic (CGIS and PGIS) and the other two are
specific for PD (HY and CISI-PD). On the other hand, three are
single-item scales (HY, CGIS, and PGIS) and one is multi-item scale
(CISI-PD).
The objective of the present study were: (1) to determine the
degree of agreement among these four global severity scales and
(2) to identify which of them is more closely associated to the
other variables in the study reflecting severity of PD-related
aspects.
Our working hypotheses were: (1) the four scales for global
assessment of PD are dissimilar in source of information and
content; therefore, the agreement between scales will be only
partial and different between rater-based and patient-based
evaluations (objective 1), and (2) if the global scales differ among
them, one of them could be more strongly associated with
other markers of disease severity and, consequently, could be
deemed the most accurate to estimate the global severity of PD
(objective 2). No prospects on the results with any particular scale
were advanced for this second hypothesis.
RESULTS
From 452 included PD patients, 433 (95.8%), 54.5% males, were
considered for analysis once 19 cases with missing values or
errors (two responses for one item or values out of range) were
dropped out. The distribution by HY was: stage 1, 13.9%; stage 2,
36.7%; stage 3, 30.2%; stage 4, 15.7%; and stage 5, 3.5%. The
demographic characteristics and PD historical data are summa-
rized in the Table 1, whereas the Table 2 shows the distribution
of the sample as per the severity levels determined for each scale.
The maximum disagreement was found for PGIS with HY and
CISI-PD, which were coincident in severity level only in 58.89% of
patients (sensitivity analysis: confidence interval = 4.63, for a 95%
confidence level).
Table 3 displays the correlation between the global scales,
which ranges from 0.60 (HY with PGIS) to 0.91 (CGIS with CISI-PD).
As a whole, highest values were obtained with the CISI-PD for all
correlations. CGIS and CISI-PD were highly correlated (rS = 0.61–
0.78) across all HY stages except stage 1 (rS = 0.40), whereas PGIS
showed a moderate correlation (rS = 0.30–0.56, except for HY
stage 5, rS =− 0.02) with the CISI-PD and a weak correlation with
the CGIS (except for HY stage 4, rS = 0.41).
Concerning the concordance of the four global scales to classify
patients as mild, moderate or severe, the lowest percentage
of agreement was observed between PGIS with HY and CISI-PD
(58%) and the highest between CGIS and CISI-PD (84.3%).
Weighted kappa followed a similar behavior (Table 4). Kendall’s
coefficient of concordance for the severity levels of the four scales
resulted 0.67 (Po0.0001) and the generalized kappa statistic was
0.52 (95% confidence interval (CI) = 0.64–0.73).
The correlation coefficients between the four global scales and
the other variables in the study are displayed in the Table 3. As a
whole, HY and CISI-PD had the highest association with time-
related variables (age and duration) and levodopa-equivalent daily
dose. CISI-PD reached the highest coefficients with measures of
PD manifestations severity (MDS-UPDRS), disability (SES and BI),
and quality of life (EQ-5D-3L, EQ-VAS, and PDQ-8). PGIS and CISI-
PD correlated similarly with HADS-A and HADS-D, at a higher level
than HY and CGIS.
DISCUSSION
This study was focused in analyzing the performance of four
simultaneously applied global assessments based on the clinician
Table 1. Descriptive data of the sample demography and assessment
Mean s.d. 95% CI Range
Age at study 65.1 10.7 64.1–66.1 22–91
Age at Parkinson’s disease onset 56.4 11.2 55.4–57.5 17–80
Parkinson’s disease duration 8.8 6.4 8.2–9.4 0–40
Years since diagnosis 7.9 6.1 7.4–8.5 0–37
Duration of treatment 7.7 6.1 7.1–8.3 0–37
Movement Disorder Society—UPDRS 1 11.1 7.0 10.6–2.0 0–34
Movement Disorder Society—UPDRS 2 15.7 11.4 14.6–16.7 0–49
Movement Disorder Society—UPDRS 3 35.7 21.1 33.7–37.7 0–97
Movement Disorder Society—UPDRS 4 4.8 5.0 4.3–5.2 0–18
Schwab and England scale 73.8 21.0 71.8–75.8 10–100
Barthel index 84.9 22.6 82.7–87.0 0–100
Hospital Anxiety Depression Scale—anxiety 7.4 3.9 7.1–7.8 0–20
Hospital Anxiety Depression Scale—depression 6.5 4.3 6.1–6.9 0–20
EQ-5D-3L 0.62 0.33 0.59–0.66 − 0.65–1
EQ Visual analog scale 63.6 23.2 61.4–65.8 0–100
Parkinson’s disease questionnaire—8 items 29.7 22.0 27.6–31.7 0–100
CISI-PD 8.6 5.1 8.1–9.1 1–21
Levodopa equivalent daily dose 774.2 488.4 728.1–820.3 0–4000
Abbreviations: CI, confidence interval; CISI-PD, Clinical Impression of Severity Index for Parkinson’s disease; EQ, EuroQoL questionnaire; EQ-5D-3L, EuroQoL
questionnaire, 5 dimensions, 3 levels; UPDRS, Unified Parkinson’s Disease Rating Scale.














Mild 50.6% 44.8% 47.6% 40.2%
Moderate 30.3% 35.1% 37.0% 38.6%
Severe 19.2% 20.1% 15.5% 21.3%
aClinical Impression of Severity Index for Parkinson’s Disease.
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(HY, CGIS and CISI-PD) and patient (PGIS). Two of these
assessments are specific PD evaluations (HY and CISI-PD) and
the other two are generic (CGIS and PGIS). They have different
ranges of scores, running from 0 to 5 for HY and PGIS to 0 to 24
(CISI-PD). Nonetheless, the four scales can be converted to a
classification in three severity levels immediately interpretable:
mild; moderate; and severe. This shared ordinal scaling allowed
analyses to determine the degree of agreement among scales,
which is influenced not only by the differences in structure and
scoring procedure, but also by the origin of the information
(patient versus clinician). In this sense, it could be expected that
rater-based global scales showed higher concordance with the
rater-based evaluations, whereas the patient global impression
would be more concordant with patient-reported outcomes.
Our results concerning the first hypothesis demonstrate that:
(1) The four scales are closely correlated between them, although
with variable strength: the strongest correlation was observed
between CGIS and CISI-PD, whereas the weakest was observed
between clinician-based scales and patient self-evaluation
(Table 3). Previous studies have reported a substantial agree-
ment between functional evaluations performed by patients
and clinicians,11,12 although patients tend to overestimate
their functional disability in comparison with doctors’
evaluations.5 These relationships can be complex and depend
on circumstances such as comorbidities or the availability of a
caregiver.5,12,13
(2) The concordance among severity levels derived from the
tested scales showed percentages of agreement from 58%
(PGIS with HY and with CISI-PD) to 84.3% (CGIS with CISI-PD)
and kappa values from 0.57 (moderate, PGIS with CISI-PD) to
0.86 (almost perfect, CGIS with CISI-PD)14 (Table 4), findings
replicating those of the correlations commented above. Both,
generalized kappa and Kendall’s concordance coefficient
showed a moderate to strong agreement amongst the
classification in severity levels from the four scales, indicating
they are not equivalent at all.
In summary, (1) the four scales show a moderate to strong
association among their scores and concordance on the severity
levels classification derived from them (Tables 3 and 4); (2) the
analyzed global scales are not equivalent, and (3) the patient-
reported evaluation correlates at a lower degree with the rater-
based scales.
Regarding the second hypothesis and once demonstrated that
the tested global scales are not equivalent, is there any of them
more closely associated, as a whole, to the diverse measures
assessing different aspects of PD? From a logical point of view, the
Table 3. Correlation between the global assessments and with the other variables in the study








Clinical global impression—Severity 0.80 — — —
Clinical Impression Severity Indexa 0.83 0.91 — —
Patient global impression severity 0.60 0.61 0.66 —
Correlations with other variables
Age at study 0.28 0.22 0.25 0.18
Age at PD onset − 0.05 − 0.08 − 0.08 − 0.03
PD duration 0.61 0.54 0.61 0.37
Years since diagnosis 0.59 0.53 0.59 0.35
Duration of treatment 0.58 0.52 0.59 0.35
MDS-UPDRS 1 0.58 0.57 0.66 0.55
MDS-UPDRS 2 0.76 0.80 0.85 0.65
MDS-UPDRS 3 0.69 0.70 0.76 0.61
MDS-UPDRS 4 0.68 0.69 0.80 0.56
Schwab and England scale − 0.81 − 0.81 − 0.85 − 0.66
Barthel index − 0.67 − 0.68 − 0.72 − 0.54
Levodopa equivalent daily dose 0.44 0.35 0.43 0.32
HADS—Anxiety 0.41 0.43 0.47 0.49
HADS—Depression 0.46 0.50 0.55 0.54
EQ-5D–3L − 0.62 − 0.67 − 0.72 − 0.62
EQ Visual analog scale − 0.55 − 0.58 − 0.62 −0.60
PDQ-8 0.66 0.70 0.74 0.67
Abbreviations: EQ, EuroQoL questionnaire; 5D–3L, 5 dimensions, 3 levels; HADS, Hospital Anxiety and Depression Scale; MDS-UPDRS, Movement Disorder
Society-Unified Parkinson’s Disease Rating Scale; PD, Parkinson’s disease; PDQ-8, Parkinson’s Disease Questionnaire—8 items.
aClinical Impression of Severity Index for Parkinson’s disease.
Table 4. Agreement between severity levels of the four scales
Hoehn and Yahr staging Clinical global impression of severitya Clinical impression of severity index
Clinical Global Impression of Severity 78.5% (0.81; 0.79–0.82) — —
Clinical Impression of Severity Indexa 79.0% (0.80; 0.79–0.82) 84.3% (0.86; 0.84–0.87) —
Patient Global Impression of Severity 58.0% (0.58; 0.53–0.61) 61.0% (0.63; 0.60–0.67) 58.0% (0.57; 0.54–0.61)
%: percentage of agreement. Between brackets, weigthed kappa and confidence intervals 95%.
aClinical Impression of Severity Index for Parkinson’s disease.
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scale achieving the closest association with all the other detailed
measures reflecting PD severity and impact (motor impairment
and complications, non-motor symptoms, disability, quality of life),
both from clinical evaluation and patient self-assessment could be
deemed the most appropriate for the overall evaluation of PD
severity. As shown in the Table 3, the CISI-PD was, as a whole, the
scale most closely correlated with any other variable measuring
severity of PD manifestations, functional disability, and impact
on quality of life. The latter is a remarkable finding, as it would
be expected that patient’s self-evaluation would be more closely
correlated with the patient-reported outcomes than rater-based
assessments. In fact, only the anxiety evaluation reached higher
correlation values with the PGIS than with clinician-based
assessments (Table 3).
When other global scale reached a higher correlation value with
other variables than the CISI-PD (HY for age, PD duration, and
levodopa-equivalent daily dose; PGIS for anxiety) the difference
was 0.01–0.03. However, CISI-PD coefficients reached values up to
0.11 and 0.24 higher than the other rater-based global scales and
PGIS, respectively (Table 3). Although these differences are not
huge, the constant closer association results suggest that the CISI-
PD would be the most appropriate instrument for global
estimation of PD severity.
PD is a complex disease with motor and non-motor symptoms
and complications. Global evaluations can provide a comprehen-
sive appraisal of the health state in a rapid manner, but HY is
based only in motor signs and functioning15 and CGIS and PGIS
are overall valuations, too broad, unspecific, and with a marked
subjective component difficult to control.16 The CISI-PD offers a
more detailed estimation of PD-related global health from four
outstanding aspects of the disorder that can be individually
monitored with this pragmatic instrument. It is designed to be
scored after the interview and examination have been carried out,
in order to capture information enough and decrease the
judgment based on the mere patient’s appearance.9,10 In addition,
CISI-PD has a higher precision (range, 0 to 24 points) than the
other scales (1 to 7 with the CGIS or 1 to 5 with the HY and PGIS).
In spite of the CISI-PD is composed of four items, it may be
considered a global evaluation because gathers the overall clinical
impression on the corresponding domains and takes seconds to
be completed. Previous studies found that CISI-PD explains 92% of
the CGIS variance and as a whole, correlated at higher level than
other global measures with a diversity of scales assessing a
diversity of PD-related manifestations and consequences.9,10,17,18
Limitations of the study are: (1) most of patients in the sample
were in HY stages 2 and 3, with stages 1, 4, and 5 relatively little
represented, a shortage usual in clinical samples with consecutive
patients from specialized settings (departments of Neurology,
specialized units); nonetheless, there were 83 patients in the HY-
based level with the lowest representation (‘severe’); (2) the
selection of patients, as patients with dementia were excluded;
the need of reliable patients’ introspection justifies this limitation,
although cognitive state is of marginal importance for HY staging;
(3) another potential limitation is related to variability depending
on multiple sites and raters, although the group has experience in
previous collaborations. On the other hand, the studied scales are
used in similar conditions as they were applied for this study and,
therefore, represent appropriately their use in daily practice and
applied research.
The characteristics of the study, with different countries and
researchers contributing, the size adjusted to acceptable levels of
certainty, and a sample characteristic of the specialized back-
ground in which the field work was carried out (and where its
outcomes will be applied) allow foreseeing close findings in future
studies on the topic with the instruments applied here.
Conclusions are: (1) the four scales applied to estimate the
global health state of PD patients are moderately to strongly
related among them and agree in their estimations moderately to
almost perfectly; (2) as expected, the clinician-based assessments
correlate closely between them and higher than with patient self-
evaluation; and (3) the CISI-PD shows, as a whole, the tightest
association with other measures of PD focused on motor and non-
motor impairment and complications, disability and, even, patient-
reported health-related quality of life assessments.
MATERIALS AND METHODS
Design
Multicenter, international, observational, cross-sectional study.6 Nine
centers from seven countries (Argentina, Chile, Colombia, Cuba, Ecuador,
Mexico, and Spain) participated in the sample recruitment. Two centers, in
Spain and United Kingdom, carried out the organization of the study and
statistical analysis. Data were collected from February to September, 2013
Patients
Consecutive patients were included if they were diagnosed with PD by a
neurologist competent in movement disorders, according to international
criteria.19 Exclusion criteria were: (1) parkinsonian syndrome different to
PD; (2) presence of any disabling condition impeding or interfering with
the evaluation of PD.
Patients with more than mild cognitive deterioration were excluded
from the analysis. The operational criterion to this purpose was: scoring ⩾ 3
in the item 1 of the MDS-UPDRS Part I and ⩾ 4 in the item Cognition of the
CISI-PD. Patients with problems to answer written questionnaires (e.g., due
to visual difficulties or action tremor) were assisted by a trained person.
General population in the participant countries is around 303.5 million,
with around 1 million of patients suffering PD.20 Sample size for this study
was calculated as a survey representative of PD population with a
confidence level 95%, a s.d. 0.5, and a confidence interval = 5. To this
purpose, 384 fully analyzable patients must be included. An additional 10%
was agreed in prevention of the missing data or mistakes. Therefore, a
minimal total sample 422 was proposed.
Ethics issues
The study was approved by the local Ethics Committee or Institutional
Review Board of each participant site. Patients gave their signed consent to
participate in the study.
Assessments
Demographic and PD historical information were collected through
interview and clinical records and the following assessments were used:
MDS-UPDRS Spanish version:21 this is a multidimensional measure for
assessment of Non-Motor Experiences of Daily Living (Part I; 13 items:
six rater-based and seven self-assessed by patient and/or by proxy),
Motor Experiences of Daily Living (Part II; 13 patient-based items); Motor
examination (Part III; 18 rater-based items with 33 scores); and Motor
complications (Part IV; 6 items, rater-based). Each item scores from
0 (normal) to 4 (severe) and total scores for each of the four domains are
obtained from the sum of the corresponding item scores.
HY:7 the original version of this classification (1, Unilateral involvement
only usually with minimal or no functional disability; to 5, Confinement to
bed or wheelchair unless aided) was used, as recommended.15
Global impression of severity: the clinician-based (CGIS), with 7 response
options1 and a 6-option patient-based (PGIS),6 with the option ‘severe’
collapsing the ‘markedly ill’ and ‘severely ill’ options, were applied in
the study.
CISI-PD:9,10 a clinical estimate of PD severity based on the impression of
the clinician about the severity of four outstanding PD aspects: motor
signs; disability; motor complications; and cognitive status. Each item-
domain scores from 0 (normal) to 6 (very severe) and a total score ranging
from 0 to 24 can be calculated.
Schwab and England Scale (SES):22 a rater-based measure of functional
independence ranked according to eleven options (from 100%, completely
independent, to 0%, completely dependent and bedridden). Scores are
obtained by interview and observation.
Barthel Index (BI):23 a generic, widely used assessment of functional
independence for activities of daily living. It is composed of 10 items and
the total score ranges from 0 to 100.
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Hospital Anxiety and Depression Scale (HADS):24 a self-rated scale for
global assessment of mood disorder. It consists of 7 items for evaluation of
anxiety and seven for depression. Each item scores from 0 (no problem) to
3 (severe problem). Scores of individual items can be summed to calculate
separate scores for anxiety (HADS-A) and depression (HADS-D). The HADS
is adequate for use in PD patients.25
EQ-5D-3L:26 a measure of health status providing a descriptive profile
and a single index value (from 0 to 1) representing the global quality of life
(preference) for clinical and economic evaluation. It has 5 items, each with
3 possible response levels. Higher scores represent worse perceived health.
In addition, a visual analog scale (EQ-VAS) from 0 (the worst) to 100 (the
best) is used to assess the global ‘health status today’. The EQ-5D is
‘recommended’ for use in PD.27
Parkinson’s Disease Questionnaire—8 items (PDQ-8):28 it includes 8 items,
each representing a dimension of the mother health-related quality of life
questionnaire PDQ-39. A summary index is obtained by summing the 8
items and standardizing on a scale of 0–100. Higher scores reflect worse
HRQoL. It has been ‘recommended’ for use in PD.27
Data analysis
Central tendency and dispersion measures (mean, s.d., 95% CI, range), as
well as proportions, were calculated for description of the variables in the
study. Levodopa-equivalent daily dose was calculated as per Tomlinson
et al.29
The paired correlation between the four global severity scales was
determined by means of the Spearman rank correlation coefficient, as they
did not meet assumptions for parametric tests.
Scores of the global severity scales were transformed to three severity
levels (mild, moderate, and severe) according to previous studies10,15 or
the response options wording itself, as follows: (1) HY: stages 1 and 2, mild;
stage 3, moderate; and stages 4 and 5, severe;15 (2) CISI-PD: 1–7, mild;
8–14, moderate; ⩾ 15, severe;10 (3) CGIS: 2–3, mild; 4, moderate; 5–7, severe;
and (4) PGIS: 1–2, mild; 3, moderate; 4–5, severe. The agreement among
these levels for each pair of scales was determined by percentage and
weighted kappa (with quadratic weights), and for all of them simulta-
neously by Kendall's coefficient of concordance and generalized kappa.30
The correlation with other variables in the study (clinical ratings and
patient-reported outcomes) was explored by means of the Spearman rank
correlation coefficient. Correlation coefficient values o0.30 were con-
sidered weak correlation and ⩾ 0.60, strong correlation.31
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